Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Sergliflozin etabonate
Другие языки:

Sergliflozin etabonate

Подписчиков: 0, рейтинг: 0
Sergliflozin etabonate
Sergliflozin etabonate 2.svg
Clinical data
Routes of
administration		 Oral
ATC code
  • none
Identifiers
  • 2-(4-methoxybenzyl)phenyl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C23H28O9
Molar mass 448.468 g·mol−1
3D model (JSmol)
  • CCOC(=O)OCC1C(C(C(C(O1)Oc2ccccc2Cc3ccc(cc3)OC)O)O)O
  • InChI=1S/C23H28O9/c1-3-29-23(27)30-13-18-19(24)20(25)21(26)22(32-18)31-17-7-5-4-6-15(17)12-14-8-10-16(28-2)11-9-14/h4-11,18-22,24-26H,3,12-13H2,1-2H3 ☒N
  • Key:QLXKHBNJTPICNF-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Sergliflozin etabonate (INN/USAN, codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline. It did not undergo further development after phase II.

Method of action

Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.

Chemistry

Etabonate refers to the ethyl carbonate group. The remaining structure, which is the active substance, is called sergliflozin.

Sergliflozin



Новое сообщение